Nanoviricides: Phase Ia/b healthy participant dosing completed; pox virus...
12.37 Mon 29 Jan 2024
Pantheon Resources: Unlocking Alaska's oil...
COVID-19 therapy trial underway, RSV trial to follow NanoViricides...
New products, MRI developments and international...
Driving forward R&D programmes while seeking...
Sonoro Gold files its preliminary economic...
Sirius Real Estate: Steadfast growth amidst economic...
Proactive research analyst John Savin speaks to Stephen Gunnion after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC). The company has successfully completed dosing in a Phase 1a COVID study, marking a major...